Myopia progression slowed with use of Abiliti 1-Day daily disposable lenses


Key takeaways:

  • Children wearing Abiliti 1-Day lenses had numerically lower axial elongation and myopia progression.
  • They were compared with a real-world control group of single-vision spectacle wearers.

DENVER — Myopia progressed more slowly across 2 years in children wearing Acuvue Abiliti 1-Day daily disposable contact lenses, according to data presented at ARVO 2026.

Chinese children who wore Abiliti 1-Day lenses (Johnson & Johnson Vision) had less axial elongation and a lower increase in myopia, on average, compared with a real-world control group, according to Alex Nixon, OD, principal research optometrist at Johnson & Johnson Vision, and colleagues.



"This study showed strong performance and safety for the Abiliti 1-Day lens," Alex Nixon, OD, said.



To learn more about the lens’ effect, Nixon and colleagues conducted a single-arm, open-label study among 70 children aged 7 to 12 years at Aier Eye Hospital, in China. They compared the results to a real-world control group of 42 children created from the clinic’s electronic health records.

Children in the control group wore single-vision spectacles, had the same inclusion criteria as the experimental group and also completed 24 months of follow-up.

Overall, 60 children completed the full follow-up with Abiliti 1-Day lenses.

After 24 months, children who wore Abiliti 1-Day lenses had lower change in axial length on average (0.23 mm) vs. real-world controls (0.5 mm). They also had less change in spherical equivalent cycloplegic autorefraction (–0.56 D vs. –1.16 D).

The researchers described both outcomes as “numerically” improved compared with the control group.

“The myopia progression results support the effectiveness of Abiliti 1-Day lenses as a myopia management option,” Nixon said.

Children wore the lenses on average for 14 hours a day, 6.8 days per week. No serious or significant adverse events related to the lens were reported.

“The findings from this study showed strong performance and safety for the Abiliti 1-Day lens, consistent with the conclusions for other multinational, randomized, controlled, double-masked trials,” Nixon said.

According to Johnson & Johnson Vision, this product is not FDA-approved and not available in the U.S.



<

Leave a Reply

Your email address will not be published. Required fields are marked *